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Abstract
Classical Markov models are defined through a stochastic transition matrix, i.e., a matrix whose
columns (or rows) are deterministic values representing transition probabilities. However, in
practice these quantities could often not be known in a deterministic manner, therefore, it is
more realistic to consider them as random variables. Following this approach, this paper is
aimed to give a technical generalization of classical Markov methodology in order to improve
modelling of stroke disease when dealing with real data. With this goal, we randomize the
entries of the transition matrix of a Markov chain with three states (susceptible, reliant and de-
ceased) that has been previously proposed to model the stroke disease. This randomization of
the classical Markov model permits the computation of the first probability density function of
the solution stochastic process taking advantage of the so-called Random Variable Transforma-
tion technique. Afterwards, punctual and probabilistic predictions are computed from the first
probability density function. In addition, the probability density functions of the time instants
until a certain proportion of the total population remains susceptible, reliant and deceased are
also computed. The study is completed showing the usefulness of our computational approach
to determine, from a probabilistic point of view, key quantities in medical decision making, such
as the cost-effectiveness ratio.
Keywords: Markov process, disease modelling, random variable transformation technique,
computing the first probability density function
1. Introduction1
Discrete Markov stochastic processes (s.p.’s) or discrete Markov chains are often applied to2
model the dynamics of medical events over evenly spaced times, n = 0, 1, 2, . . . , usually referred3
to as periods or cycles. In particular, these kind of s.p.’s have been considered for different4
purposes. For example, to built and simulate models for chronic illnesses [1, 2], to analyse5
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data of hospital infection [3], to provide predictions based on random-effects Markov models6
applied to multiple sclerosis progression [4], to calculate the prevalence of certain diseases and7
to perform budget impact analysis [5], to model human papilloma virus [6], etc. In these models8
individuals are classified in several disjoint classes or states. The evolution of the percentage (or9
number of individuals) in each cycle n is determined by the initial distribution of the individuals10
and a stochastic matrix, usually termed transition matrix. An important assumption of standard11
Markov models is that all the states make up a closed system. This means that any individuals12
can neither leave nor join the system, hence having a constant population size over the time.13
This hypothesis holds in the clinical context where doctors and public health authorities are14
often interested in the evolution of patient groups in controlled studies over the time. In the15
case of discrete homogeneous Markov s.p.’s, the transition matrix is a constant matrix whose16
entries represent the probabilities to change either from one state to another or to remain in the17
same state between two consecutive cycles. When these probabilities depend upon time, the18
s.p. is termed non-homogeneous time discrete Markov chains. In both cases, the entries of the19
transition matrix are assumed to be deterministic quantities (numbers or functions, respectively).20
In this paper, we generalize this feature for discrete homogeneous Markov chains by considering21
that the entries in the transition matrix could be random variables (r.v.’s) rather than deterministic22
constants. Naturally, the r.v.’s are assumed to take values in the interval [0, 1], thus representing23
probabilities for every realization of such r.v.’s. In this manner, we allow for more flexibility when24
probabilities are assigned. Throughout this paper, we will consider this approach to generalize25
the stroke disease model proposed in [7]. It is important to point out that the application of our26
approach is not limited to the stroke disease model presented later but is also valid for modelling27
any disease via time discrete homogeneous Markov chains.28
The manuscript is organized as follows. In Section 2 we introduce the mathematical stroke29
model that will be considered throughout this paper. Section 3 is addressed to give the mathemat-30
ical tools that will be required to study the stroke model. The reader more interested in medical31
results, can skip this section in a first reading. Section 4 is devoted to provide a probabilistic so-32
lution of the randomized Markov model (1)–(2) by means of the first probability density function33
for each subpopulation, susceptible, reliant and deceased. For the sake of clarity we have divided34
this section into two subsections. First, in Subsection 4.1 the main statistical properties, such as,35
the mean, the variance and confidence intervals, are computed. Secondly, Subsection 4.2 is ad-36
dressed to obtain the probabilistic distribution until a given proportion of the population remains37
susceptible. In Section 5 we perform a cost-effectiveness analysis taking advantage of the mathe-38
matical tools presented in Section 3. In Section 6, all the theoretical results developed throughout39
Sections 4 and 5 are applied to simulate the stroke disease taking particular distributions for the40
random input data that are in agreement with the extant literature. In Section 7, we discuss our41
main findings.42
2. Motivating problem: the stroke disease43
Markov/semi-Markov models have demonstrated to be useful mathematical representations44
to model diseases. In particular, this approach has been successfully applied to study the stroke45
disease using different statistical techniques [7, 8, 9]. According to [7], the stroke disease can46
be modelled via a Markov chain considering the three following states, Susceptible (S ), Reliant47
(R) and Deceased (D). In Figure 1 we show the influence or flow diagram associated to the48
Markov model. In this graphical representation, transitions among states have been included.49
We observe that, apart from remaining in each state, the possible transitions between states are50
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Figure 1: Flow diagram for the Markov model (1)–(2). S , R and D stand for Susceptible (S ), Reliant (R) and Deceased
(D), respectively.
S → R, S → D and R → D. Thus, the reliant population cannot recover from the disease.51
Obviously, the state D is an absorbing state. In this study the susceptible individuals make up a52
population at risk, i.e., they have certain pathologies (hypertension, cholesterol, etc.) that may53
conduct to suffer a stroke. Therefore, as we shall see below, the model involves a relative risk.54
In [7], the Markov model is formulated as follows55  S n+1Rn+1Dn+1
 = T
 S nRnDn
 , (S 0,R0,D0)> = (s0, r0, d0)>, n = 0, 1, 2, . . . ,
where S n, Rn and Dn are the proportion of susceptible, reliant and deceased subpopulations in56
cycle n, respectively. As a matter of fact in dealing with markovian models, we will assume that57
S n +Rn +Dn = 1 for each n. As it is plausible from a practical standpoint, we assume that initially58
there are no deaths, hence the initial cohort corresponds with the deterministic vector (s0, r0, 0)>,59
s0 + r0 = 1. Otherwise, the subsequent analysis follows analogously. Moreover, according to60
results given in [7], we shall assume that the transition matrix T is given by61
T =
 e
−t1rr + e−(t2+t3(rr−1)) −1 0 0
1 − e−t1rr 1 − p 0
1 − e−(t2+t3(rr−1)) p 1
 ,
being62
• rr is the relative risk of suffering a stroke,63
• t1 is the non-mortal stroke rate,64
• t2 is the deceased rate due to any cause,65
• t3 is the stroke death rate and,66
• p is the probability of the transition R→ D,67
where the rates t1, t2 and t3 are given for a general population. For sake of clarity, we now explain68
the construction of the transition matrix, T , in connection with [7, Table 3] and the meaning of the69
parameters previously introduced. The element (2, 1) of matrix T , T21, represents the probability70
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of suffering a non-mortal stroke in the cycle n + 1 given that the individual was susceptible in71
the cycle n (S → R). The probability of having a stroke is given by 1 minus the probability of72
does not have it, being these kind of probabilities usually modelled by an exponential decay. In73
Table 3 of [7] this probability is given by 1 − e-(“non-mortal stroke rate”). The “non-mortal stroke rate”74
is given by t1 and taking into account that we are dealing with a population under risk, this leads75
to the term t1rr. T31 denotes the probability of the transition S → D. In Table 3 of [7], this76
probability is given by 1− e−(“death rate”). Observe that the “death rate” involved in T31 is given by77
the (t2 + t3(rr − 1)) = t2 − t3 + t3 rr, that is, the non-stroke death rate for a general population,78
t2 − t3, adding the term corresponding to the stroke death rate for the population under risk given79
by t3 rr.80
At this point it is important to remark that the parameter rr though is termed relative risk, in81
the context of medicine is a positive number [10, 11].82
83
Remark 1. From a mathematical standpoint the parameters t1, t2, t3 and rr must satisfy the84
condition 0 < T21 + T31 < 1. This guarantees that T11 ∈]0, 1[. As in practice the rates t1, t2 and85
t3 are small, former condition holds.86
As it has been pointed out previously, a major difference with respect to contribution [7] is87
that we will assume that some model parameters, namely, t2, rr and p, involved in transition ma-88
trix T are absolutely continuous r.v.’s rather than deterministic constants. Hereinafter, as usual in89
Probability Theory, capital letters will be used to highlight this difference. Hence, the following90
identifications, t2 ⇒ T2, rr ⇒ RR and p⇒ P, will be used (see expression (2)). This decision is91
motivated inasmuch as, in practice, the death rate due to any cause, T2, is not known in a deter-92
ministic way and the relative risk of suffering a stroke, RR, varies among physical characteristic93
of individuals being this variation non-deterministic. Regarding parameter P, which represents a94
probability, we assume that it can be described by a r.v. whose domain is contained in the interval95
]0, 1[, allowing for more flexibility throughout the study. In the following, the triplet (Ω,F ,P)96
will denote the common complete probability space where r.v.’s T2, RR and P are defined.97
Summarizing the model that we are going to study is98  S n+1Rn+1Dn+1
 = T
 S nRnDn
 , (S 0,R0,D0)> = (s0, r0, 0)>, n = 0, 1, 2, . . . , (1)
where the transition matrix is given by99
T =
 e
−t1RR + e−(T2+t3(RR−1)) −1 0 0
1 − e−t1RR 1 − P 0
1 − e−(T2+t3(RR−1)) P 1
 . (2)
In connection with Remark 1 and, in the random context, to guarantee the positiveness of the100




0 < T21(ω) + T31(ω) = 2 − e−t1RR(ω) − e−(T2(ω)+t3(RR(ω)−1)) < 1
]
= 1, ∀ω ∈ Ω. (3)
To conduct our study, the so-called Random Variable Transformation (RVT) method will be103
used [12]. This technique has been successfully applied in previous contributions related to epi-104
demiological models, some examples include [13, 14, 15, 16]. RVT method allows us to obtain105
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the first probability density function (1-p.d.f.) of the solution s.p.’s, S n, Rn, Dn, to model (1)–(2).106
Additionally, we will compute the p.d.f.’s of times until a given proportion of the population re-107
mains susceptible, reliant and deceased, respectively. Finally, the p.d.f. of the cost-effectiveness108
ratio will be also computed taking advantage of RVT technique. This is a key quantity in medical109
decision making.110
3. Mathematical tools111
We start stating the key mathematical tool, usually referred to as Random Variable Transfor-112
mation (RVT) method, that we will used in Sections 4 and 5 to give a full probabilistic solution113
of the disease stroke markovian model formulated in (1)–(2).114
Theorem 1. (Multidimensional version, [12, pp. 24–25]). Let U = (U1, . . . ,Un)> and V =115
(V1, . . . ,Vn)> be two n-dimensional absolutely continuous random vectors. Let g : Rn → Rn be a116
one-to-one deterministic transformation of U into V, i.e., V = g(U). Assume that g is continuous117
in U and has continuous partial derivatives with respect to U. Then, if fU(u) denotes the joint118
probability density function of vector U, and h = g−1 = (h1(v1, . . . , vn), . . . , hn(v1, . . . , vn))>119
represents the inverse mapping of g = (g1(u1, . . . , un), . . . , gn(u1, . . . , un))>, the joint probability120
density function of vector V is given by121
fV(v) = fU (h(v)) |J| , (4)






















In the subsequent subsection the RVT method is applied to determine the 1-p.d.f. of the123
solution s.p. to stroke model (1)–(2). This function will permit later to compute important124
statistical properties of the solution to the stroke model, namely, the mean and standard deviation125
functions of susceptible, reliant and deceased subpopulations. In addition, RVT technique will126
play a key role to compute the p.d.f. of the time until a given proportion of the population remains127
in some of the three states (susceptible, reliant and deceased). This will be illustrated later.128
3.1. First probability density function129
As it has been said previously, the goal of this subsection is to obtain the 1-p.d.f. of the130
number of susceptibles, reliants and deceaseds, which are the components of the solution s.p.131
of the random initial value problem (1)–(2). This will be done in terms of the random input132
data. For the sake of generality as it has been indicated previously, throughout this subsection133
RR, T2 and P are assumed to be absolutely continuous dependent r.v.’s, defined on a common134
probability space (Ω,F ,P), with joint p.d.f. fRR,T2,P(rr, t2, p) defined on a domain, say DRR,T2,P.135
It generalizes the case where RR, T2 and P are assumed to be independent r.v.’s with p.d.f.’s136
fRR(rr), fT2 (t2) and fP(p), since in that case fRR,T2,P(rr, t2, p) = fRR(rr) fT2 (t2) fP(p). Although137
less general, independence is a hypothesis usually embraced in probabilistic applications.138
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As it is well known, the solution of (1)– (2) is139  S nRnDn
 = T n
 s0r00
 . (6)
To conduct our study it is convenient to recast the entries of the transition matrix T as follows140
T =
 1 − K − Q 0 0K 1 − P 0Q P 1
 , (7)





(1 − K − Q)ns0
(1 − K − Q)nKs0 − (1 − P)n(r0(−P + Q + K) + Ks0)
P − Q − K
r0 − r0(1 − P)n +
(P − Q + (−P + Q)(1 − Q − K)n + (−1 + (1 − P)n)K)s0
P − Q − K

. (8)
Notice that as P, Q and K are absolutely continuous r.v.’s, the denominator of second and third143
components of expression (8) are non-zero with probability 1. Taking into account S n+Rn+Dn =144
1 for each n, it is enough to determine the 1-p.d.f. of susceptible and reliant subpopulations, since145
from them, it is straightforward to obtain the 1-p.d.f. of deceased subpopulation.146
This goal will be achieved by applying RVT method twice. First, we will compute the147
joint p.d.f., fS n,Rn,P(s, r, p), of random vector (S n,Rn, P) from the joint p.d.f., fK,Q,P(k, q, p), of148
(K,Q, P), and secondly, we will compute the joint p.d.f., fK,Q,P(k, q, p), of (K,Q, P) from the149
joint p.d.f., fRR,T2,P(rr, t2, p), of random input data (RR,T2, P).150
Now, we fix the cycle n and use the RVT method. Then, we apply Theorem 1 with the
following identifications
U = (K,Q, P)>, V = (V1,V2,V3), V = g(U)>,
g : R3 → R3, g(k, q, p) = (g1(k, q, p), g2(k, q, p), g3(k, q, p))> = (v1, v2, v3)>,
being
v1 = (1 − k − q)ns0, v2 =
(1 − k − q)nks0 − (1 − p)n (r0(−p + q + k) + ks0)
p − q − k
, v3 = p.
Isolating k, q and p one gets151
k =
(







(r0(1 − v3)n − v2)






























For the sake of clarity, hereinafter we will consider m1 := k and m2 := q.152













nv1(v1 − s0(1 − v3)n)
.
Then, taking into account (4)–(5), the joint p.d.f. of random vector (V1,V2,V3) = (S n,Rn, P) is154
given by155













nv1(v1 − s0(1 − v3)n)
∣∣∣∣∣∣∣∣∣∣ . (10)
Using again Theorem 1 with the following identifications156
U = Û = (RR,T2, P)>, V = V̂ = (V̂1, V̂2, V̂3), V̂ = g(Û)>,
157
g : R3 → R3, g(rr, t2, p) = (g1(rr, t2, p), g2(rr, t2, p), g3(rr, t2, p))> = (v̂1, v̂2, v̂3)>,
being158
v̂1 = 1 − e−t1rr, v̂2 = 1 − e−(t2+t3(rr−1)), v̂3 = p,
and isolating rr, t2 and p, one gets159
rr =
− log (1 − v̂1)
t1
, t2 = t3 +
t3 log (1 − v̂1)
t1
− log (1 − v̂2), p = v̂3.
Moreover, the Jacobian of the mapping g−1 is160
J =
1
t1(1 − v̂1)(1 − v̂2)
.
Then, taking into account (4)–(5), the joint p.d.f. of random vector (V̂1, V̂2, V̂3) = (K,Q, P) is161
given by162
fK,Q,P(v̂1, v̂2, v̂3) = fRR,T2,P
(
− log (1 − v̂1)
t1
, t3 +
t3 log (1 − v̂1)
t1
− log (1 − v̂2), v̂3
)
×
∣∣∣∣∣ 1t1(1 − v̂1)(1 − v̂2)
∣∣∣∣∣ .
(11)
Compounding both (10) and (11), we determine the joint p.d.f. of (S n,Rn, P) using the p.d.f.163
of the random vector (RR,T2, P)164
fS n,Rn,P(s, r, p) = fRR,T2,P
(
− log (1 − m1)
t1
, t3 +
t3 log (1 − m1)
t1
− log (1 − m2), p
)
×


















where m1 and m2 are the expressions introduced in (9) and below using the identifications v1 ⇒ s,165
v2 ⇒ r and v3 ⇒ p.166
Finally, considering n arbitrary and marginalizing (12), we obtain the 1-p.d.f.’s of the sub-167










t3 log(1 − m1)
t1
− log(1 − m2), p
)
×


























t3 log(1 − m1)
t1
− log(1 − m2), p
)
×














ns (s − s0 (1 − p)n)
∣∣∣∣∣∣∣∣∣∣ dp ds.
(14)
Now, we will provide the 1-p.d.f. of the deceased subpopulation, using that Dn = 1 − S n −169
Rn, for each cycle n. To this end, first we apply Theorem 1 again considering the following170
identifications171
U = (S n,Rn)>, V = (V1,V2), V = g(U)>,
172
g : R2 → R2, g(s, r) = (g1(s, r), g2(s, r))> = (v1, v2)>,
being173
v1 = 1 − s − r, v2 = r.
Isolating s and r one gets174
s = 1 − v1 − v2, r = v2.
Then, taking into account (4)–(5) and that the Jacobian takes the value −1, we obtain the joint175
p.d.f. of random vector (V1,V2) = (Dn,Rn). Finally, marginalizing this latter joint p.d.f. and176











t3 log(1 − m1)
t1
− log(1 − m2), p
)
×


















4. A full probabilistic solution of the stroke markovian model179
The 1-p.d.f. gives a full probabilistic description in each period n of the solution s.p. of a180
markovian model. In particular, the 1-p.d.f. of susceptibles, reliants and deceaseds to the stroke181
markovian model (1)–(2) are given by (13), (14) and (15), respectively. It is important to point182
out that all these expressions are given by closed-form formulas.183
Moreover, from the 1-p.d.f., both the mean and variance functions can be straightforwardly184
computed for every state of the model. This information is crucial in order to provide punc-185
tual and probabilistic predictions. In medical practice it is also important to know when the186
percentage of susceptibles, reliants and deceaseds in the population will achieve a certain level.187
This information can be determined by means of the 1-p.d.f. as well. These ideas motivate the188
following two subsections.189
4.1. Mean and variance functions. Confidence intervals190
Hereinafter, we will focus on susceptible subpopulation, S n, whose 1-p.d.f. is given by (13),191
although the following development can be extrapolated to reliant and deceased subpopulations,192
using (14) and (15), respectively. The expressions for the mean and the variance functions are193
µS n = E [S n] =
∫
DS n
s f1(s, n) ds, σ2S n = V [S n] =
∫
DS n





Furthermore, the 1-p.d.f. is useful to construct confidence intervals. Let α ∈ (0, 1) and n̂195
fixed, one can determine s1 = s1(n̂) and s2 = s2(n̂) such that196 ∫ s1
0






f1(s, n̂) ds. (17)
Then, (1 − α) × 100%-confidence interval is specified by197
1 − α = P ({ω ∈ Ω : S (n̂;ω) ∈ [s1, s2]}) =
∫ s2
s1
f1(s, n̂) ds. (18)
In addition, it is of interest for doctors knowing the probability, for example, that the proportion198
of susceptible subpopulation lies between a and b at a specific time period, say n̂,199
P[a ≤ S n̂ ≤ b] =
∫ b
a
f1(s, n̂) ds. (19)
4.2. Distribution of time until a given proportion of the population remains susceptible, reliant200
or deceased201
In practice, it is useful to know when the percentage of susceptibles, reliants and deceaseds202
in the population will attain a certain level. This motivates the computation, in a first step, of the203
distribution, NS , of the time until a given proportion of the population, ρS , remains susceptible.204
The same can be said for reliant and deceased subpopulations.205
In order to compute the p.d.f. of Ns for a fixed proportion of susceptibles, ρS , we first isolate206










e−t1RR + e−(T2+t3(RR−1)) −1
) . (20)
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Notice that expression (20) depends only on r.v.’s RR and T2. Hence we apply RVT technique,209
i.e., Theorem 1 to210
U = (RR,T2)>, V = (V1,V2), V = g(U)>,
211
g : R2 → R2, g(rr, t2) = (g1(rr, t2), g2(rr, t2))> = (v1, v2)>,
being212








e−t1rr + e−(t2+t3(rr−1)) −1
) .
Isolating rr and t2, one gets213
rr = v1, t2 = t3(1 − v1) − log
(ρSs0
)1/v2
+ 1 − e−t1v1
.


















Then, taking into account (4)–(5) we obtain the joint p.d.f. of random vector (V1,V2) = (RR,Ns).215
Finally, marginalizing with respect to r.v. RR, the expression of the p.d.f. of NS , for each ρS216
fixed, is217




rr, t3(1 − rr) − log (ρSs0
)1/n






















5. Probabilistic cost-effectiveness analysis218
The cost-effectiveness analysis is useful to perform an economic evaluation of sanitary in-219
terventions. Incremental cost-effectiveness ratio, CE, can be used in order to prioritise sanitary220
interventions and then maximizing benefits taking into account available budgets [17, 18]. CE is221





where Ci, and Ei, i = 1, 2, are the cost and the effectiveness of the alternative i, respectively.223
Hereinafter, we assume that Ci and Ei, i = 1, 2 are r.v.’s. In the following, we will compute224
the 1-p.d.f. of the CE to compare two treatments for the stroke disease, being the second more225
effective than the first, but the first cheaper. Then, differences between both are the transition226
matrix T (particularly the relative risk) and the cost. To obtain the 1-p.d.f. of the CE, first we227
will determine the expression of the total effectiveness given by the QALY (Quality Adjusted228
10
Life Year), for each treatment. In the context of medical Markov models, the QALY has already229
been used, see for instance [19]. QALY is the sum of the effectiveness of susceptibles, reliants230
and deceaseds. In addition, these three effectivenesses are the sum of the effectiveness in each231
cycle until the value n of total years considered for the study. This effectiveness is the product232
of number of susceptibles, reliants or deceaseds in each cycle 1 ≤ j ≤ n, the utility appropriate233
for each state and a certain constant, which depends on a discount rate r. These magnitudes will234
be detailed later. With this aim, we need to know the utility, or the value of life’s quality, where235
0 value corresponds to death and 1 value represents that stroke disease has not been suffered by236
individuals, [2, 7, 20]. Then, we will consider US = 1 and UD = 0 the utilities of susceptibles237
and deceaseds, respectively. For reliants, we will model the utility, say UR, through a r.v. Taking238
into account the extant literature, we consider r = 0.03 (3%) as the discount rate [7, 21, 22].239










(1 + r) j−1
, i = 1, 2, (24)
where E[S j,i] and E[R j,i] are the average number of susceptibles and reliants of alternative i =241
1, 2, for each cycle j, 1 ≤ j ≤ n, respectively. The second step is to determine the expression242
of the total cost of each treatment. We will follow the same structure that in the case of the243
QALY. On the one hand, we will consider that the cost of the each treatment for susceptible244
subpopulation is CS i = ai W, where ai is the cost, in euros, of medicine per kilogram and W is a245
r.v. that represents the weight of the individual to be studied. On the other hand, we will consider246
that the dependence cost is a r.v., denoted by CR. This r.v. is assumed to be the same in both247
treatments. Then, the cost in each treatment is248









(1 + r) j−1
, i = 1, 2. (25)
Substituting expressions (24)–(25) into (23), one gets249
CE =
W d1 + CR d2








































(1 + r) j−1
.
Now, applying RVT technique, i.e. Theorem 1, we obtain the 1-p.d.f. of CE from the p.d.f. of251






ce(d3 + ur d2) − cr d2
d1
, cr, ur
) ∣∣∣∣∣d3 + ur d2d1
∣∣∣∣∣ durdcr. (26)
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6. Simulating the stroke disease using real data253
In this section, we will show the results (simulations) for the Markov model (1)–(2) in order254
to study the stroke disease. These simulations are built using the results established in Sections255
4 and 5 and considering the medical information from [7].256
As it is plausible from a practical standpoint, hereinafter we will assume that, at the begin-257
ning, the whole population is susceptible, then, the initial condition is (s0, r0, 0)> = (1, 0, 0)>.258
Based upon [7], the following probability distributions for model inputs parameters are consid-259
ered:260
• The relative risk, RR, is a lognormal r.v. with parameters (1.793; 0.143), i.e., log(RR) ∼261
N(1.793; 0.143).262
• The transition R → D is modelled by r.v. P, which is assumed to be a beta distribution263
with parameters (80; 120), i.e., P ∼ Be(80; 120).264
• The deceased rate due to any cause, T2, is assumed to be a r.v. with a uniform distribution265
on the interval ]0.02127, 0.02227[, T2 ∼ U(]0.02127, 0.02227[).266
With regard to the non-mortal stroke rate, t1, and the stroke deceased rate, t3, it is assumed267
that t1 = 0.00111 and t3 = 0.00176, respectively. These values have been taken from reference268
[7], taking into account that these rates correspond to a group of individuals with 65 years old.269
Notice that the previous theoretical results can be applied because the r.v.’s RR and T2, with the270
distributions specified above, satisfy condition (3).271
In Figure 2, the 1-p.d.f.’s of susceptible, reliant and deceased subpopulations, given by ex-272
pressions (13)–(15), have been plotted. These graphical representations have been made in peri-273
ods {1, 2, . . . , 25}, assuming that r.v.’s RR, P and T2 are independent. From Figure 2, we observe274
that the percentage of susceptibles decreases as time increases. Besides, the percentage of reliant275
increases at the beginning, specifically from n = 1 to n = 6, and afterwards this percentage tends276
to zero.277
On the other hand, the deceased subpopulation is an absorbent state, therefore in the long-278
term all the population will reach this state. This behaviour is in agreement with the results279
shown in Figure 2. From this graphical representation it can be observed that both the percent-280
age of dead and its variability increase over time. This same behaviour is observed to susceptible281
subpopulation for the periods plotted in Figure 2, although it will decrease as time goes on. Fi-282
nally, the shape of the 1-p.d.f., f1(r, n), depicted in Figure 2 becomes sharp as standard deviation283
decreases.284
In Figure 3, the mean plus/minus standard deviation functions of the three subpopulations are285
shown. Notice that graphical representations exhibited in Figure 2 and Figure 3 are in agreement.286
We point out that the computation of the 1-p.d.f. is very useful in applications since from287
it, as we have seen previously in Subsection 4.1, one can compute exact confidence intervals288
in order to construct probabilistic predictions. In addition, it permits the computation of the289
probability associated to sets of interest. For instance, from expression (19) applied to the reliant290
subpopulation, we can obtain the probability that the proportion of reliants that lies between291
a = 0.010 (1%) and b = 0.015 (1.5%) in the time period n̂ = 5 is, approximately 0.7,292
P[0.010 ≤ R5 ≤ 0.015] =
∫ 0.015
0.010






























































Figure 2: Plot of the 1-p.d.f.’s: f1(s, n) given by (13) (top); f1(r, n) given by (14) (middle); f1(d, n) given by (15) (bottom)
at the values n ∈ {1, 2, . . . , 25}.
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Figure 4: Plot of the p.d.f. of the time NS until a proportion ρS ∈ {0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9} of the population
remains susceptible.
Table 1: Expectation of time NS until a proportion, ρS , of the population remains susceptible for different values ρS .
ρS 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
E[NS ] 42.9520 32.1312 24.4538 18.4980 13.6327 9.5189 5.9553 2.8118
Now, we will determine the p.d.f.’s of time until a given proportion of the population remains293
susceptible, reliant or deceased. For susceptible subpopulation this has been done using expres-294
sion (22). Figure 4 shows this p.d.f. for the following values of ρS ∈ {0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9}.295
From the p.d.f. of NS , we can compute the expectation of r.v. NS for a fixed value of ρS , like296
0.70,297
E [NS ] =
∫ ∞
0
n f1(n, 0.70) dn = 9.5190.
This means that, approximately, the middle of 10-th cycle (since the study starts at n = 0)298
represents the average time until 70% of the population will be susceptible. This can also be299
seen graphically in Figure 4. Table 1 collects the expectation, E [NS ], for different values of ρS .300
This is a key information for doctors when they want to study the evolution of susceptibles of301
stroke disease in a group of patients.302
In order to obtain the p.d.f.’s of r.v.’s NR and ND, that denote the time until a proportion303
of population, ρR and ρD, remains reliant or deceased, respectively, we have applied numerical304
methods. We have made this decision because n cannot be isolated from the second and third305
components of the solution given by (8). To illustrate the process that we have followed to carry306
out computations, below we specify the steps for reliant subpopulation where ρR is assumed to307
be fixed:308
• Step 1: To sample 500 000 values, say (rr, t2, p), according to the specific distributions309
assumed for r.v.’s RR, T2 and P.310
• Step 2: For each sampled value (rr, t2, p), to apply Newton method to calculate the value311
n of NR solving the nonlinear equation defined by the second component of (8), that cor-312
responds to the reliant subpopulation, substituting RR ⇒ rr, T2 ⇒ t2 and P ⇒ p. This313
process provides 500 000 values for n of NR.314
• Step 3: To plot the histogram of 500 000 values of n. A normalization of this histogram is315
an approximation of the p.d.f. of NR.316
15

















Figure 5: Plot of the p.d.f. of the time NR until a proportion ρR = 0.006 of the population remains reliant, using as seed
points sp = 1 (left) and sp = 25 (right).







Figure 6: Plot of the p.d.f. of the time NR until a proportion ρR = 0.0183 of the population remains reliant, using as seed
point sp = 2.
Since the numerical convergence of Newton method heavily depends on the seed or starting317
point, say sp, for example, in the case that ρR = 0.006, we have obtained two graphical represen-318
tations for the p.d.f. of NR, that are shown in Figure 5. Specifically, taking the values sp = 1 and319
sp = 25, the p.d.f. of the time NR has been obtained for cycles n = 1 and n = 30, respectively.320
This is due because the proportion of reliants reaches the value ρR = 0.006 in those two cycles.321
Whereas for the case ρR = 0.0183, the Newton method always converges for the cycle n = 5,322
thus defining a single p.d.f. for NR. This p.d.f. has been plotted in Figure 6 taking as seed value323
sp = 2.324
Regarding the deceased subpopulation, we have followed the same steps described previ-325
ously. In Figure 7, we have plotted the p.d.f. of ND for the following values of percentage326
ρD ∈ {0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9}, where sp = 3 has been taken as the seed point, for327
each value of ρD. In this case, to every value of ρD corresponds a unique value of n.328
Finally, we will compute the 1-p.d.f. of CE given by (26). From it, the mean and confidence329
intervals will also be computed. This will be done for different ages, 30, 65 and 71. This decision330
has been made because the involved rates for each age are different. Computations have been331
carried out taking the following probability distributions for random inputs:332
• The relative risk for the first alternative (the less efficient), RR1, is a lognormal r.v. with333





















Figure 7: Plot of the p.d.f. of the time ND until a proportion ρD ∈ {0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9} of the population
remains dead.
• The relative risk for the second alternative (the most efficient), RR2 = RR1 B, where B is335
the benefit.336
• B is a lognormal r.v. with parameters (−0.964; 0.163), i.e., log(B) ∼ N(−0.964; 0.163).337
• The transition R → D is modelled by r.v. P, which is assumed to be a beta distribution338
with parameters (80; 120), i.e., P ∼ Be(80; 120).339
• The deceased rate due to any cause, T2, is assumed to be a r.v. with a uniform distribution340
on the interval ]t2 − 0.0001, t2 + 0.0001[, i.e., T2 ∼ U(]t2 − 0.0001, t2 + 0.0001[), where t2341
is a fixed value, which depends on age, and that will be specified below.342
• The dependence cost, CR, is a lognormal r.v. with parameters (6.936; 0.643), i.e., log(CR) ∼343
N(6.936; 0.643).344
• The weight, W, is a normal r.v. with parameters (75.900; 12.290), i.e., W ∼ N(75.900; 12.290).345
The prices of both treatments are a1 = 6.5e/kg and a2 = 65e/kg, [7].346
• The utility, UR, is a normal r.v. with parameters (0.701; 0.347) i.e., UR ∼ N(0.701; 0.347).347
Above, t1, t2 and t3 are rates, which depend on age of the population under study. In Figure 8,348
we show the expectation of susceptibles, reliants and and deceaseds for the two alternatives in349
the three ages. For each one of them, we have considered the following rates, t1, t2 and t3, which350
are based on [7], and end cycles values, nmax,351
• For age of 30 years: t1 = 0.0000298, t2 = 0.00169, t3 = 0.00004 and nmax = 69.352
• For age of 65 years: t1 = 0.0011135, t2 = 0.02177, t3 = 0.00176 and nmax = 34.353
• For age of 71 years: t1 = 0.0031780, t2 = 0.03616 and t3 = 0.00373 and nmax = 28.354
Notice that this study is until 99 years, but we could choose another age limit. From Figure 8,355
we can observe, in all the ages, that the mean of susceptibles with the second treatment is greater356
17

































































































Figure 8: Plots of expectation of susceptibles, reliants and deceaseds for the two alternatives 1 (the cheapest) and 2 (the




































































Figure 9: P.d.f.’s de CE given by (26) considering both alternatives in the three ages: 30 years (left), 65 years (center)
and 71 years (right).
than considering the first, and the reverse for the expectation of reliants and deceaseds. This is357
consistent with the fact that the second alternative is better than the first.358
In Figure 9 we have plotted the 1-p.d.f.’s of the CE, given by (26), for each age from cycle 1359
to 34. Notice that graphical representations shown in Figure 9 are in agreement with Figure 10,360
where expectation plus/minus standard deviation functions of CE for each age have been plotted.361
To facilitate comparison between both alternatives, the value 30 000e/QALY (red straight line)362
has also been plotted as a threshold. This benchmark value has been chosen because, according363
to [23], is a standard value in the literature. From Figure 10, we can observe that for people364
aged 71 years old the second alternative (the most expensive), is more effective than the first365
alternative. Naturally, for people aged 30 years old, the best alternative is the first one because366
they have longer lifetime. For people aged 65 years old, it might be controversy because their367
CE is very close to the threshold.368
7. Discussion369
Although Markov models have been used extensively for modelling the dynamics of numer-370
ous diseases, to the best of our knowledge, few attempts have been made regarding the stroke371
disease. The markovian approach is useful to perform the clinical control of patients that suffer372
this disease. Indeed, Markov models allow us to forecast not only the number of patients be-373
longing to each subpopulation (susceptibles, reliants and deceaseds) at every cycle but also to374
account for significant medical information. In this regard, the time until a given proportion of375
patients remain susceptible, reliant or deceased are, for example, important information in the376
medical treatment of the stroke. This is a key information to answer crucial questions like “what377
is the expected time before twenty percent, for instance, of the population remains susceptible?”.378
In this paper, we have given a technical generalization of classical Markov methodology that379
enables the exact determination of the crucial medical information previously indicated. This380
generalization is aimed to improve the modelling of stroke disease when dealing with real data,381
19
































Figure 10: Plots of expectation plus/minus standard deviation functions of CE for each age considering both alternatives
in the three ages: 30 years (left), 65 years (center) and 71 years (right). The red straight line represents the threshold
value 30 000e/QALY usually taking as reference [23].
although an important issue is that this technique can easily be adapted to another diseases using382
the markovian paradigm. Our approach resorts in the so-called Random Variable Transformation383
method to randomize classical Markov chains. This randomization has been done through some384
of the entries of the transition matrix of a classical Markov chain which has been previously pro-385
posed to model the stroke disease. Our approach allows us the computation of the first probability386
density function of the solution stochastic process, and then obtaining punctual and probabilistic387
predictions as well as the important probabilistic information that we have underlined previously.388
Moreover, we have conducted a probabilistic cost-effectiveness analysis, based on the appli-389
cation of the Random Variable Transformation technique, that to the best of our knowledge, has390
not been done yet. The main advantage of this computational approach is that results can be391
obtained in an exact manner rather than using simulations.392
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[21] X. Badia, H. Bueno, J. R. González-Juanatey, V. Valentı́n, M. Rubio, Análisis de la relación coste-efectividad448
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